RARA and breast carcinoma: For instance, opposing effects of RARα and ERα agonists35, evidence of cooperativity between these two TFs36, their similar DNA binding preferences, and association of RARα with drug resistance in breast cancer cells37 make RARα’s role in the ERα transcriptional program particularly controversial.